Tenohep is used to treat in patients suffering chronic hepatitis B and decompensated liver diseases In adult and children 12yrs and >12yrs the drug Tenohep is indicated for the treatment with combination of other antiretroviral agent to treat HIV-1 infection.
Tenofovir is sold under the trade name Tenohep and belongs to anticancer drugs, it is a medication used for treatment of chronic hepatitis B and to prevent and treat HIV/AIDS. Tenohep show activity against HIV-1 reverse transcriptase.
The drug require for the use with other antiretrovirals. Tenohep is a prescription drugs given under supervision of doctor or pharmacist.
In adult Tenohep is used to treat in patients suffering chronic hepatitis B and decompensated liver diseases In adult and children 12yrs and >12yrs the drug Tenohep is indicated for the treatment with combination of other antiretroviral agent to treat HIV-1 infection.
MECHANISM OF ACTION
When patient cell attack with HIV, then the HIV virus will take the cell under control of, then the virus grow repeated copies in the cell. For this process the virus needed an enzyme. When the activity of those enzymes is reduces the multiplication of HIV slows down. Tenohep is nucleoside reverse transcriptase inhibitors (NRTIs). These inhibitor blocks the action of an HIV enzyme known as reverse transcriptase, in which the protein (enzyme) raises the speed of a chemical reaction. NRTIs interferes HIV from proliferation and reduces the amount of HIV in the body by stopping reverse transcriptase.
Rapid absorbed from GI tract, bioavailability (25%) The time to peak plasma concentration of Tenohep is 1-2hrs.
the drug bounding of human serum protein is >1% and it is widely distributed into body tissue especially in kidney and liver ( volume of distribution is 1.2-1.3L/kg).
TenofovirDisoproxil Fumarate is converted into Tenohep through hydrolysis by cellular enzyme through phosphorylation. and to form active Tenohep diphosphate . ELIMINATION: By active tubular secretion and glomerular Tenohep excreted via urine. Half life of Tenohep is 18hr.
DOSAGE AND ADMINISTRATION
In adult 12yrs and older: 300mg If patient not able to shallow take oral powder formulation of 7.5 scoops In pediatric 2yrs and <12yrs : 8 mg recommended dose. If patient not able to shallow take oral powder formulation is 1 level scoop=1 g powder contains 40mg of Tenvirdisoporxil. ≥ 17kg Tenohep dos available in different strengths 150, 200, 250 and 300mg. One tablet of Tenohep 300mg, once daily without food, taken orally.
The drug has no severe adverse reaction for effect of higher dose and treatment provides of general supportive measures involves monitoring of evidence of toxicity and patients clinical status observation.
Hepatomegaly suffering patients or other severe factors for liver problem.Renal impairment. Pregnant women Patient Counselling Tenohep may cause dizziness, do not drive or operate machinery.
Renal function and serum phosphate concentrations prior to therapy, 4 wkly in 1st wk, and then 3 mthly; hepatic function for several month following discontinuation. Determine HIV condition in all hepatitis B virus (HBV) infected patients before treatment. Allergy to Tenohep or any other drug.Before inform with doctor about allergic to any drugs. Such as rash; hives; itching; Dyspnea; wheezing; cough; swelling of (face, lips, tongue, or throat); or any other signs.
If you had kidney or liver disease and taking colchicines then inform your doctor, he may stop the Tenohep drug. Inform your doctor that you are pregnant or plan for pregnancy or breast feeding, while you infected with HIV or taking Tenohep tablet avoid breast feed.
Mild nausea, stomach ache, insomnia, itching and rashes, Change in body shape (fat) Signs of allergic reaction Hives, Dyspnea, Swelling of (face,lips,throat,tongue) Severe hepatomegaly with steatosis Chest pain Wheezing Cold sore Fast heart rate Lumbar pain
When Tenohep interaction with didanosine and HIV-1 protease inhibitors then increase didanosine concentration and results in adverse effects like pancreatitis and neuropathy Interaction with HIV-1 protease inhibitors such as atazanavir will reduces atazanavir concentration while increase the Tenohep concentrations
Category B : Animal studies have shown an adverse effect in fetus, so sufficient and well-developed studies in pregnant women have failed give detail about a risk to the fetus in all trimester.
Tenohep 300mg is preferably safe to use during breastfeeding. Limited information on the risk for the baby. Please consult with doctor
The drug stored at 25°C(77°) and keep container tightly closed Dispense the drug only in original container
If missed to take a dose ,leave the dose and take your next dose at the normal time or take it as soon as you remember and take your next dose at the normal time. Do not have the extra dose to make up for a missed dose. Please consult with the doctor.